Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2

Cobos-Campos et al., Clin. Res. Trials, 2021, doi:10.15761/CRT.1000333, Jan 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/coboscampos.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,200+ studies for 180+ treatments. c19early.org

Review finding that there appears to be sufficient evidence to recommend ivermectin for the treatment of COVID-19, especially in the early stages of the disease.

7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.

Currently there are 106 ivermectin for COVID-19 studies, showing 47% lower mortality [34‑58%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 79% fewer cases [69‑86%].

Important missing comments or errors? Let us know.

1. Bryant et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402.lww.com, doi.org.

2. Hariyanto et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Reviews In Medical Virology, doi:10.1002/rmv.2265.wiley.com, doi.org.

3. Kory et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.lww.com, doi.org.

4. Lawrie et al., Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance, Preprint, b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdffilesusr.com.

5. Nardelli et al., Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?, Signa Vitae, doi:10.22514/sv.2021.043.signavitae.com, doi.org.

6. Zein et al., Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.102186.sciencedirect.com, doi.org.

7. Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.sciencedirect.com, doi.org.

Cobos-Campos et al., 29 Jan 2021, peer-reviewed, 9 authors.

This Paper Ivermectin All

DOI record: { "DOI": "10.15761/crt.1000333", "ISSN": [ "2059-0377" ], "URL": "http://dx.doi.org/10.15761/CRT.1000333", "author": [ { "affiliation": [], "family": "Alvarado González", "given": "Alcibey", "sequence": "first" } ], "container-title": "Clinical Research and Trials", "container-title-short": "Clin Res Trials", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 3, 24 ] ], "date-time": "2021-03-24T08:32:16Z", "timestamp": 1616574736000 }, "deposited": { "date-parts": [ [ 2021, 3, 24 ] ], "date-time": "2021-03-24T08:32:22Z", "timestamp": 1616574742000 }, "indexed": { "date-parts": [ [ 2023, 6, 8 ] ], "date-time": "2023-06-08T07:32:06Z", "timestamp": 1686209526930 }, "is-referenced-by-count": 1, "issue": "1", "issued": { "date-parts": [ [ 2020 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2020 ] ] } }, "member": "6817", "original-title": [], "prefix": "10.15761", "published": { "date-parts": [ [ 2020 ] ] }, "published-online": { "date-parts": [ [ 2020 ] ] }, "publisher": "Open Access Text Pvt, Ltd.", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://www.oatext.com/ige-diseases.php" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "IgE Diseases", "type": "journal-article", "volume": "7" }

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0